	US 12,186,388 B2
	Interferon-producing universal sarbecovirus vaccines, and uses thereof
Kin Hang Kok, Hong Kong (HK)
Assigned to CENTRE FOR VIROLOGY, VACCINOLOGY AND THERAPEUTICS LIMITED, Hong Kong (HK)
Filed by Centre for Virology, Vaccinology and Therapeutics Limited, Hong Kong (HK)
Filed on Feb. 6, 2023, as Appl. No. 18/165,286.
Claims priority of provisional application 63/382,009, filed on Nov. 2, 2022.
Prior Publication US 2024/0139307 A1, May 2, 2024
Int. Cl. A61K 39/215 (2006.01); A61P 31/14 (2006.01); C12N 7/00 (2006.01); A61K 39/00 (2006.01)

CPC A61K 39/215 (2013.01) [A61P 31/14 (2018.01); C12N 7/00 (2013.01); A61K 2039/543 (2013.01); C12N 2770/20022 (2013.01); C12N 2770/20034 (2013.01); C12N 2770/20071 (2013.01)]

20 Claims

1. A construct comprising a modified genome of a sarbecovirus, wherein the modified genome of the sarbecovirus comprises a modified envelope gene of the sarbecovirus and a nucleic acid encoding an interferon integrated into the modified genome of the sarbecovirus, wherein the modified envelope gene of the sarbecovirus comprises one or more stop codons, wherein the modified envelope gene of the sarbecovirus does not produce a functional envelope protein of the sarbecovirus, and wherein the construct is replication incompetent as a result of the modified envelope gene of the sarbecovirus not producing functional envelope protein of the sarbecovirus.